miltefosine has been researched along with Canine Diseases in 22 studies
miltefosine: hexadecyl phosphocholine derivative of cisplatin; did not substantially activate HIV long terminal repeat; less toxic than cisplatin
miltefosine : A phospholipid that is the hexadecyl monoester of phosphocholine.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The safety of miltefosine-allopurinol combination therapy was confirmed by lack of effect on renal and hepatic parameters and adverse reactions." | 2.74 | Multicentric, controlled clinical study to evaluate effectiveness and safety of miltefosine and allopurinol for canine leishmaniosis. ( Bianciardi, P; Cañavate, C; Cruz, I; Miró, G; Mortarino, M; Oliva, G; Vischer, C, 2009) |
| "Canine visceral leishmaniasis is an endemic zoonosis in Brazil." | 1.72 | Clinical and parasitological impact of short-term treatment using miltefosine and allopurinol monotherapy or combination therapy in canine visceral leishmaniasis. ( Almeida, ADBPF; Ayres, EDCBS; Barbosa, MEC; Dias, ÁFLR; Dutra, V; Macedo, LFDC; Monteiro, BRG; Nakazato, L; Pazzini, SS; Silva, EBD; Sousa, VRF, 2022) |
| "Miltefosine was authorized to treat canine leishmaniasis (CanL) in Brazil in 2017, but there is a persistent fear of the emergence of parasites resistant not only to this drug but, through cross-resistance mechanisms, also to meglumine antimoniate and amphotericin B." | 1.62 | Increased Leishmania infantum resistance to miltefosine and amphotericin B after treatment of a dog with miltefosine and allopurinol. ( Campos, MP; Figueiredo, FB; Gonçalves, AS; Gonçalves, G; Medeiros, LCS, 2021) |
| "Miltefosine was significantly more efficacious than marbofloxacin (P < 0." | 1.38 | Canine leishmaniosis: in vitro efficacy of miltefosine and marbofloxacin alone or in combination with allopurinol against clinical strains of Leishmania infantum. ( Badino, P; Farca, AM; Ferroglio, E; Miniscalco, B; Monticelli, P; Odore, R; Trisciuoglio, A, 2012) |
| "2%) presented product-related adverse events concerning the gastrointestinal tract." | 1.35 | Comparative study on the short term efficacy and adverse effects of miltefosine and meglumine antimoniate in dogs with natural leishmaniosis. ( Bianciardi, P; Mateo, M; Maynard, L; Miró, G; Vischer, C, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (22.73) | 29.6817 |
| 2010's | 8 (36.36) | 24.3611 |
| 2020's | 9 (40.91) | 2.80 |
| Authors | Studies |
|---|---|
| Gonçalves, G | 2 |
| Campos, MP | 2 |
| Gonçalves, AS | 1 |
| Medeiros, LCS | 1 |
| Figueiredo, FB | 2 |
| Ayres, EDCBS | 2 |
| Dias, ÁFLR | 2 |
| Monteiro, BRG | 1 |
| Pazzini, SS | 1 |
| Barbosa, MEC | 1 |
| Silva, EBD | 1 |
| Macedo, LFDC | 1 |
| Sousa, VRF | 2 |
| Dutra, V | 1 |
| Nakazato, L | 1 |
| Almeida, ADBPF | 2 |
| Matralis, DT | 1 |
| Koutinas, AF | 1 |
| Papadogiannaki, IE | 1 |
| Papadopoulos, EG | 1 |
| Papadogiannakis, EI | 1 |
| de Jong, MK | 1 |
| Rappoldt, A | 1 |
| Broere, F | 1 |
| Piek, CJ | 1 |
| Tirado, TC | 1 |
| Negrão, DD | 1 |
| Silva, GMPD | 1 |
| Poleto, APCM | 1 |
| Hartin, TP | 1 |
| Silva, JBA | 1 |
| Castilhos, MMS | 1 |
| Ramos, RAN | 1 |
| Giannelli, A | 1 |
| Fasquelle, F | 1 |
| Scuotto, A | 1 |
| Betbeder, D | 1 |
| de Oliveira Martins, DT | 1 |
| Maruyama, FH | 1 |
| de Oliveira, RG | 1 |
| de Carvalho, MR | 1 |
| Teixeira, ALS | 1 |
| Mendonça, AJ | 1 |
| Olías-Molero, AI | 1 |
| Fontán-Matilla, E | 1 |
| Cuquerella, M | 1 |
| Alunda, JM | 1 |
| Monteiro, M | 1 |
| Prata, S | 1 |
| Cardoso, L | 1 |
| Pereira da Fonseca, I | 1 |
| Leal, RO | 1 |
| Travi, BL | 1 |
| Cordeiro-da-Silva, A | 1 |
| Dantas-Torres, F | 1 |
| Miró, G | 4 |
| Dos Santos Nogueira, F | 1 |
| Avino, VC | 1 |
| Galvis-Ovallos, F | 1 |
| Pereira-Chioccola, VL | 1 |
| Moreira, MAB | 1 |
| Romariz, APPL | 1 |
| Molla, LM | 1 |
| Menz, I | 1 |
| Daza González, MA | 1 |
| Fragío Arnold, C | 1 |
| Fermín Rodríguez, M | 1 |
| Checa, R | 1 |
| Montoya, A | 1 |
| Portero Fuentes, M | 1 |
| Rupérez Noguer, C | 1 |
| Martínez Subiela, S | 1 |
| Cerón, JJ | 1 |
| Maia, C | 1 |
| Nunes, M | 1 |
| Marques, M | 1 |
| Henriques, S | 1 |
| Rolão, N | 1 |
| Campino, L | 1 |
| Manna, L | 3 |
| Corso, R | 1 |
| Galiero, G | 1 |
| Cerrone, A | 1 |
| Muzj, P | 1 |
| Gravino, AE | 3 |
| Tangalidi, MK | 1 |
| Oikonomidis, IL | 1 |
| Psalla, D | 1 |
| Papadimitriou, S | 1 |
| Kritsepi-Konstantinou, M | 1 |
| Mylonakis, ME | 1 |
| Vitale, F | 2 |
| Reale, S | 2 |
| Picillo, E | 2 |
| Neglia, G | 1 |
| Vescio, F | 1 |
| Mateo, M | 1 |
| Maynard, L | 2 |
| Vischer, C | 2 |
| Bianciardi, P | 2 |
| Woerly, V | 1 |
| Sanquer, A | 1 |
| Eun, HM | 1 |
| Oliva, G | 1 |
| Cruz, I | 1 |
| Cañavate, C | 1 |
| Mortarino, M | 1 |
| Andrade, HM | 1 |
| Toledo, VP | 1 |
| Pinheiro, MB | 1 |
| Guimarães, TM | 1 |
| Oliveira, NC | 1 |
| Castro, JA | 1 |
| Silva, RN | 1 |
| Amorim, AC | 1 |
| Brandão, RM | 1 |
| Yoko, M | 1 |
| Silva, AS | 1 |
| Dumont, K | 1 |
| Ribeiro, ML | 1 |
| Bartchewsky, W | 1 |
| Monte, SJ | 1 |
| Farca, AM | 1 |
| Miniscalco, B | 1 |
| Badino, P | 1 |
| Odore, R | 1 |
| Monticelli, P | 1 |
| Trisciuoglio, A | 1 |
| Ferroglio, E | 1 |
1 review available for miltefosine and Canine Diseases
| Article | Year |
|---|---|
Canine visceral leishmaniasis: Diagnosis and management of the reservoir living among us.
Topics: Allopurinol; Animals; Antiprotozoal Agents; Disease Reservoirs; Dog Diseases; Dogs; Leishmania infan | 2018 |
4 trials available for miltefosine and Canine Diseases
| Article | Year |
|---|---|
Intracellular IFN-γ and IL-4 levels of CD4 + and CD8 + T cells in the peripheral blood of naturally infected (Leishmania infantum) symptomatic dogs before and following a 4-week treatment with miltefosine and allopurinol: a double-blinded, controlled and
Topics: Allopurinol; Animals; CD8-Positive T-Lymphocytes; Cross-Sectional Studies; Dog Diseases; Dogs; Inter | 2023 |
Long-term follow-up of dogs with leishmaniosis treated with meglumine antimoniate plus allopurinol versus miltefosine plus allopurinol.
Topics: Allopurinol; Animals; Antiprotozoal Agents; Dog Diseases; Dogs; Drug Therapy, Combination; Female; F | 2015 |
Clinical efficacy and tolerance of miltefosine in the treatment of canine leishmaniosis.
Topics: Administration, Oral; Animals; Antiprotozoal Agents; Dog Diseases; Dogs; Female; Leishmaniasis, Visc | 2009 |
Multicentric, controlled clinical study to evaluate effectiveness and safety of miltefosine and allopurinol for canine leishmaniosis.
Topics: Allopurinol; Animals; Dog Diseases; Dogs; Drug Therapy, Combination; Female; Leishmaniasis, Cutaneou | 2009 |
17 other studies available for miltefosine and Canine Diseases
| Article | Year |
|---|---|
Increased Leishmania infantum resistance to miltefosine and amphotericin B after treatment of a dog with miltefosine and allopurinol.
Topics: Allopurinol; Amphotericin B; Animals; Antiprotozoal Agents; Dog Diseases; Dogs; Drug Resistance; Fem | 2021 |
Clinical and parasitological impact of short-term treatment using miltefosine and allopurinol monotherapy or combination therapy in canine visceral leishmaniasis.
Topics: Allopurinol; Animals; Antiprotozoal Agents; Dog Diseases; Dogs; Leishmania infantum; Leishmaniasis, | 2022 |
Survival time and prognostic factors in canine leishmaniosis in a non-endemic country treated with a two-phase protocol including initial allopurinol monotherapy.
Topics: Allopurinol; Animals; Creatinine; Dog Diseases; Dogs; Humans; Leishmania infantum; Leishmaniasis; Le | 2023 |
A case of canine visceral leishmaniasis of unknown origin in Curitiba (state of Paraná, Brazil) treated successfully with miltefosine.
Topics: Animals; Brazil; Dog Diseases; Dogs; Female; Leishmaniasis, Visceral; Male; Phosphorylcholine | 2023 |
Effective immuno-therapeutic treatment of Canine Leishmaniasis.
Topics: Animals; Dog Diseases; Dogs; Leishmania infantum; Leishmaniasis; Leishmaniasis, Visceral | 2023 |
Comparative study of the use of miltefosine, miltefosine plus allopurinol, and allopurinol in dogs with visceral leishmaniasis.
Topics: Allopurinol; Animals; Antiprotozoal Agents; Cytokines; Dog Diseases; Dogs; Drug Therapy, Combination | 2020 |
Scientometric analysis of chemotherapy of canine leishmaniasis (2000-2020).
Topics: Allopurinol; Amphotericin B; Animals; Antiprotozoal Agents; Dog Diseases; Dogs; Drug Combinations; D | 2021 |
Diagnosis and clinical management of canine leishmaniosis by general veterinary practitioners: a questionnaire-based survey in Portugal.
Topics: Adult; Allopurinol; Animals; Antiprotozoal Agents; Dog Diseases; Dogs; Female; Humans; Knowledge; Le | 2021 |
Use of miltefosine to treat canine visceral leishmaniasis caused by Leishmania infantum in Brazil.
Topics: Administration, Oral; Animals; Antiprotozoal Agents; Dog Diseases; Dogs; Female; Insect Vectors; Lei | 2019 |
Effect of two treatments on changes in serum acute phase protein concentrations in dogs with clinical leishmaniosis.
Topics: Acute-Phase Proteins; Allopurinol; Animals; Antiprotozoal Agents; Aryldialkylphosphatase; Dog Diseas | 2019 |
In vitro drug susceptibility of Leishmania infantum isolated from humans and dogs.
Topics: Allopurinol; Amphotericin B; Animals; Antiprotozoal Agents; Deoxycholic Acid; Disease Reservoirs; Do | 2013 |
Nodular granulomatous glossitis as the sole clinical sign in canine leishmaniosis.
Topics: Allopurinol; Animals; Antiprotozoal Agents; Dog Diseases; Dogs; Drug Therapy, Combination; Fluoresce | 2016 |
Study of efficacy of miltefosine and allopurinol in dogs with leishmaniosis.
Topics: Allopurinol; Animals; Antiprotozoal Agents; Disease Models, Animal; Disease Reservoirs; Dog Diseases | 2009 |
Interferon-gamma (INF-gamma), IL4 expression levels and Leishmania DNA load as prognostic markers for monitoring response to treatment of leishmaniotic dogs with miltefosine and allopurinol.
Topics: Allopurinol; Animals; Antiprotozoal Agents; Biomarkers; DNA, Protozoan; Dog Diseases; Dogs; Interfer | 2008 |
Comparative study on the short term efficacy and adverse effects of miltefosine and meglumine antimoniate in dogs with natural leishmaniosis.
Topics: Administration, Oral; Animals; Antiprotozoal Agents; Bone Marrow; Dog Diseases; Dogs; Female; Inject | 2009 |
Evaluation of miltefosine for the treatment of dogs naturally infected with L. infantum (=L. chagasi) in Brazil.
Topics: Animals; Antiprotozoal Agents; Brazil; Dog Diseases; Dogs; Immunoglobulin G; Leishmania infantum; Le | 2011 |
Canine leishmaniosis: in vitro efficacy of miltefosine and marbofloxacin alone or in combination with allopurinol against clinical strains of Leishmania infantum.
Topics: Allopurinol; Animals; Antiprotozoal Agents; Dog Diseases; Dogs; Drug Synergism; Fluoroquinolones; Le | 2012 |